DrugBiological
Sifalimumab clinical trials
Also written MEDI-545.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of Immunologic Factors source
Studies
Open first, then newest update. How each study uses sifalimumab is read from its arms, and is right about nine times in ten.
Testing it · 8
- A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus.CompletedPhase 2AstraZenecaNCT01031836Written as MEDI-545
- A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus ErythematosusCompletedPhase 2MedImmune LLCNCT01283139Written as Sifalimumab 200 mg
- A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or MyositisCompletedPhase 2MedImmune LLCNCT00979654Written as Sifalimumab
- A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With LupusCompletedPhase 2MedImmune LLCNCT00657189Written as MEDI-545
- A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus ErythematosusCompletedPhase 1MedImmune LLCNCT00482989Written as MEDI 545
- A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or PolymyositisCompletedPhase 1MedImmune LLCNCT00533091Written as MEDI-545
- A Multicenter Study to Evaluate the Safety and Tolerability of Single-Dose for MEDI-545CompletedPhase 1MedImmune LLCNCT00472758Written as MEDI 545
- Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)CompletedPhase 1MedImmune LLCNCT00299819Written as MEDI-545
Codes
What other systems call sifalimumab · ClinicalTrials.gg INT005928
- MeSH (NLM) C568334sifalimumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) XOY1YA7RMCSIFALIMUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q7511830sifalimumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C95061SifalimumabOne source FDA
- DrugBank DB12773One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C568334 | sifalimumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | XOY1YA7RMC | SIFALIMUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7511830 | sifalimumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C95061 | Sifalimumab | One source FDA |
| DrugBank | DB12773 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.